| Business Summary | | MedImmune,
Inc.
is
a
biotechnology
company
with
five
products
on
the
market
and
a
diverse
portfolio
of
products
in
development.
The
Company
is
focused
on
using
advances
in
immunology
and
other
biological
sciences
to
develop
important
new
products
that
address
significantly
unmet
medical
needs
in
areas
of
infectious
disease
and
immune
regulation.
The
Company
also
focuses
on
oncology
through
its
wholly
owned
subsidiary,
MedImmune
Oncology,
Inc.
The
Company
launched
Synagis
in
the
United
States
for
preventing
respiratory
syncytial
virus
in
high-risk
pediatric
patients.
The
Company
also
markets
CytoGam
and
RespiGam,
and
has
several
product
candidates
undergoing
clinical
trials.
Through
MedImmune
Oncology's
sales
and
marketing
group,
the
Company
also
markets
Ethyol
and
NeuTrexin. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | MEDI
is
focused
on
using
advances
in
immunology
and
other
biological
sciences
to
develop
important
new
products
that
address
significant
medical
needs
in
areas
such
as
infectious
diseases,
transplantation
medicine,
autoimmune
diseases
and
cancer.
For
the
six
months
ended
6/01,
revenues
rose
16%
to
$278.6
million.
Net
income
before
acct.
change
rose
22%
to
$69.4
million.
Results
reflect
increased
sales
of
Synagis
and
increased
interest
income
due
to
higher
cash
balances. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Wayne Hockmeyer, Ph.D., 56 Chairman | $1.4M | $33M | Melvin Booth, 56 Pres,
COO, Director | 988K | 47M | David Mott, 35 Vice
Chairman, CEO | 1.3M | 29M | Gregory Patrick, 49 CFO,
Sr. VP | -- | -- | James Young, Ph.D., 48 Pres,
R&D | 706K | 13M | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|